NELFA
Negative elongation factor A
Also known as: NELF-A, NELFA_HUMAN, WHSC2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9H3P2
- Gene
- NELFA
- Ensembl
- ENSG00000185049
- Chromosome
- 4
- Canonical length
- 528 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Nuclear bodies
OverviewNCBI Gene
This gene is expressed ubiquitously with higher levels in fetal than in adult tissues. It encodes a protein sharing 93% sequence identity with the mouse protein. Wolf-Hirschhorn syndrome (WHS) is a malformation syndrome associated with a hemizygous deletion of the distal short arm of chromosome 4. This gene is mapped to the 165 kb WHS critical region, and may play a role in the phenotype of the WHS or Pitt-Rogers-Danks syndrome. The encoded protein is found to be capable of reacting with HLA-A2-restricted and tumor-specific cytotoxic T lymphocytes, suggesting a target for use in specific immunotherapy for a large number of cancer patients. This protein has also been shown to be a member of the NELF (negative elongation factor) protein complex that participates in the regulation of RNA polymerase II transcription elongation. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
528 residues, UniProt reviewed canonical sequence.
>Q9H3P2|NELFA
1 MASMRESDTG LWLHNKLGAT DELWAPPSIA SLLTAAVIDN IRLCFHGLSS AVKLKLLLGT
61 LHLPRRTVDE MKGALMEIIQ LASLDSDPWV LMVADILKSF PDTGSLNLEL EEQNPNVQDI
121 LGELREKVGE CEASAMLPLE CQYLNKNALT TLAGPLTPPV KHFQLKRKPK SATLRAELLQ
181 KSTETAQQLK RSAGVPFHAK GRGLLRKMDT TTPLKGIPKQ APFRSPTAPS VFSPTGNRTP
241 IPPSRTLLRK ERGVKLLDIS ELDMVGAGRE AKRRRKTLDA EVVEKPAKEE TVVENATPDY
301 AAGLVSTQKL GSLNNEPALP STSYLPSTPS VVPASSYIPS SETPPAPSSR EASRPPEEPS
361 APSPTLPAQF KQRAPMYNSG LSPATPTPAA PTSPLTPTTP PAVAPTTQTP PVAMVAPQTQ
421 APAQQQPKKN LSLTREQMFA AQEMFKTANK VTRPEKALIL GFMAGSRENP CQEQGDVIQI
481 KLSEHTEDLP KADGQGSTTM LVDTVFEMNY ATGQWTRFKK YKPMTNVSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NELFA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.54
- Highest tissue expression
- 28 nTPM
Expression across tissuesHPA
Tissue
- esophagus: 28 nTPM
- skin: 26 nTPM
- ovary: 25 nTPM
- testis: 24 nTPM
- cerebellum: 23 nTPM
- vagina: 22 nTPM
Single-cell type
- ependymal cells: 223 nCPM
- sertoli cells: 204 nCPM
- granulosa cells: 130 nCPM
- esophageal apical cells: 93 nCPM
- retinal horizontal cells: 92 nCPM
- choroid plexus epithelial cells: 89 nCPM
Immune cell
- naive B-cell: 24 nTPM
- T-reg: 22 nTPM
- MAIT T-cell: 19 nTPM
- memory CD4 T-cell: 18 nTPM
- plasmacytoid DC: 17 nTPM
- intermediate monocyte: 17 nTPM
Brain region
- white matter: 27 nTPM
- cerebral cortex: 26 nTPM
- midbrain: 26 nTPM
- medulla oblongata: 26 nTPM
- basal ganglia: 25 nTPM
- spinal cord: 25 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about NELFA.
Disease | ImmuneIEDB
Conditions an epitope on NELFA was assayed in.
- castration-resistant prostate carcinoma B and T cell
- prostate cancer B and T cell
- prostate adenocarcinoma B and T cell
- biliary tract cancer B and T cell
- esophageal cancer B and T cell
- carcinoma B and T cell
- triple-receptor negative breast cancer B and T cell
- Her2-receptor negative breast cancer B and T cell
- Her2-receptor positive breast cancer B and T cell
- colorectal cancer B and T cell
- synovial sarcoma B and T cell
- leiomyosarcoma B and T cell
- lung cancer B and T cell
- prostatic urethral cancer B and T cell
- cancer B cell
- pancreatic carcinoma B cell
- lung small cell carcinoma B cell
- adult hepatocellular carcinoma B cell
- hematologic cancer B cell
- hepatocellular carcinoma B cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.51
- gnomAD pLI
- 0.13
- gnomAD missense Z
- 1.82
- DepMap mean gene effect
- -0.91
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- negative regulation of transcription elongation by RNA polymerase II
- positive regulation of transcription by RNA polymerase II
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Hepatitis delta antigen (HDAg) domain
- Negative elongation factor A domain-containing protein
- NELF-A, N-terminal domain
- NELF-A N-terminal domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of NELFA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NELFA as an antibody target. Whether an autoantibody or antibody against NELFA could matter depends on whether native NELFA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NELFA is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NELFA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...